Inventor · disambiguated record
Stephen Sunghan Yoo
Also filed as: YOO STEPHEN · YOO STEPHEN S · YOO STEPHEN SUNGHAN
13 granted patents·19 pending applications·13 citations·filing 2016–2025
86Inventor score
Top patents by PatentIndex Score
32 records- 0184US10836827B2Antibodies specific to glycosylated PD-L1 and methods of use thereofSTCUBE INC·Filed 2016·Granted Nov 17, 2020·3 cites·24 claims
- 0283US10858432B2Antibodies specific to glycosylated PD-1 and methods of use thereofSTCUBE INC·Filed 2016·Granted Dec 8, 2020·3 cites·23 claims
- 0380US11253590B2Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator)STSCIENCES INC·Filed 2016·Granted Feb 22, 2022·3 cites·30 claims
- 0475US11542331B2Methods of treating cancer using antibodies and molecules that bind to BTN1A1 or BTN1A1-ligandsSTCUBE & CO INC·Filed 2018·Granted Jan 3, 2023·1 cites·18 claims
- 0574US2025129159A1Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1STCUBE & CO INC·Filed 2024·Application pending·0 cites
- 0673US2024343797A1Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereofSTCUBE & CO INC·Filed 2024·Application pending·0 cites
- 0772US10875920B2Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereofSTCUBE & CO INC·Filed 2016·Granted Dec 29, 2020·1 cites·11 claims
- 0872US2024254214A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2023·Application pending·0 cites
- 0971US11660352B2Dual function antibodies specific to glycosylated PD-L1 and methods of use thereofSTCUBE INC·Filed 2017·Granted May 30, 2023·1 cites·28 claims
- 1071US11613739B2Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) produced by human neural or glial cellsREGENXBIO INC·Filed 2018·Granted Mar 28, 2023·1 cites·16 claims
- 1171US2025059276A1Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereofSTCUBE & CO INC·Filed 2024·Application pending·0 cites
- 1268US2025327803A1Screening methods for targets for cancer therapySTCUBE & CO INC·Filed 2025·Application pending·0 cites
- 1367US11981736B2Antibodies specific to glycosylated PD-1 and methods of use thereofSTCUBE INC·Filed 2020·Granted May 14, 2024·0 cites·19 claims
- 1467US2025051740A1Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cellsREGENXBIO INC·Filed 2024·Application pending·0 cites
- 1566US2023057519A1Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2022·Application pending·0 cites
- 1666US2023279112A1Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligandsSTCUBE & CO INC·Filed 2022·Application pending·0 cites
- 1764US2025320287A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2025·Application pending·0 cites
- 1863US2024050537A1Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)REGENXBIO INC·Filed 2023·Application pending·0 cites
- 1961US11970534B2Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereofSTCUBE & CO INC·Filed 2020·Granted Apr 30, 2024·0 cites·13 claims
- 2058US2025189530A1Btn1a1 binding proteins and methods of use thereofSTCUBE & CO INC·Filed 2023·Application pending·0 cites
- 2157US12215151B2Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1STCUBE & CO INC·Filed 2018·Granted Feb 4, 2025·0 cites·20 claims
- 2256US11933786B2Antibodies specific to glycosylated PD-L1 and methods of use thereofSTCUBE INC·Filed 2020·Granted Mar 19, 2024·0 cites·19 claims
- 2356US2019211091A1Treatment of Ocular Diseases with Fully-Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2019·Application pending·0 cites
- 2455US2020277364A1TREATMENT OF OCULAR DISEASES WITH FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTI-VEGF FabREGENXBIO INC·Filed 2018·Application pending·0 cites
- 2550US2020148768A1Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereofSTCUBE & CO INC·Filed 2018·Application pending·0 cites
- 2650US2019127455A1Treatment of Ocular Diseases with Fully- Human Post-Translationally Modified Anti-VEGF FabREGENXBIO INC·Filed 2017·Application pending·0 cites
- 2747US2019358303A1Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)REGENXBIO INC·Filed 2018·Application pending·0 cites
- 2843US12059474B2Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteinsSTCUBE & CO INC·Filed 2017·Granted Aug 13, 2024·0 cites·22 claims
- 2943US2022411511A1Antibodies specific to glycosylated ctla-4 and methods of use thereofSTCUBE & CO·Filed 2020·Application pending·0 cites
- 3042US11746152B2Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1STCUBE INC·Filed 2017·Granted Sep 5, 2023·0 cites·13 claims
- 3142US2018156800A1Screening methods for targets for cancer therapySTCUBE & CO INC·Filed 2016·Application pending·0 cites
- 3240US2021275647A1Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)REGENXBIO INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stephen Sunghan Yoo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →